Peripheral Vascular Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End User, By Region & Competition, 2021-2031F

The Global Peripheral Vascular Devices Market is projected to expand from USD 10.71 billion in 2025 to USD 16.09 billion by 2031, exhibiting a 7.02% Compound Annual Growth Rate (CAGR). This market comprises interventional medical instruments, such as stents, catheters, angioplasty balloons, and atherectomy systems, specifically designed for treating vascular diseases that affect blood vessels outside the heart and brain. Growth is primarily underpinned by the increasing global prevalence of peripheral artery disease (PAD), which is closely linked to an aging population and the rising incidence of lifestyle-related conditions like diabetes and obesity. Moreover, a significant shift in clinical preference from traditional open surgical revascularization to minimally invasive endovascular procedures acts as a powerful driver, as these modern methods offer patients reduced recovery times and lower complication rates. However, a major market challenge stems from the high rate of underdiagnosis and limited disease awareness among the general public. Delayed detection often leads to disease progression beyond the point where device-based intervention is effective, consequently limiting the addressable market size, with over 68% of Americans reportedly unaware of peripheral artery disease in 2025, according to the Society for Vascular Surgery. This critical gap in patient education significantly hinders early screening efforts and restricts the global utilization of peripheral vascular interventions.

Market Driver

The escalating incidence of diabetes and related lifestyle comorbidities stands as a primary catalyst for the Global Peripheral Vascular Devices Market. Chronic hyperglycemia and obesity accelerate atherosclerosis progression, directly increasing patient susceptibility to peripheral artery disease (PAD) and critical limb ischemia, thereby creating a sustained demand for interventional therapies to prevent amputations. In 2025, approximately 11.1% of the global adult population was living with diabetes, as reported by the International Diabetes Federation's 'IDF Diabetes Atlas 11th Edition,' highlighting a vast and expanding patient pool requiring ongoing vascular management. Concurrently, a paradigm shift towards minimally invasive endovascular interventions, coupled with continuous technological innovation, is significantly propelling the market. Clinicians increasingly favor catheter-based techniques over traditional open surgery due to superior patient outcomes, including shorter hospital stays and reduced procedural risks. This transition is further supported by advancements in device capabilities, such as drug-coated balloons and next-generation stent platforms, which drive higher procedural volumes. For instance, Abbott's Medical Devices segment reported a 14.0% organic sales increase in its 'Fourth-Quarter and Full-Year 2024 Results' (January 2025), reflecting strong adoption of its interventional technologies. Similarly, Medtronic's Cardiovascular Portfolio generated $12.481 billion in annual revenue in 'Fiscal Year 2025 Financial Results' (May 2025), underscoring robust global expenditure on vascular care solutions.

Market Challenge

The substantial rates of underdiagnosis and low disease awareness fundamentally constrain the revenue potential of the global peripheral vascular devices market by limiting the volume of treatable patients. Device manufacturers depend on the early identification of candidates for minimally invasive interventions such as angioplasty or stenting. However, symptoms like leg pain are often dismissed by patients as normal signs of aging, preventing a significant portion of the affected population from seeking medical advice until their condition becomes severe. This delay results in a considerable contraction of the addressable market, as missed diagnoses directly translate into fewer procedural opportunities for utilizing advanced vascular technologies. This challenge is further exacerbated by a lack of proactive clinical engagement with high-risk populations. In 2025, 80% of Black and Hispanic adults reported that a healthcare provider had never discussed peripheral artery disease with them, according to the Society for Cardiovascular Angiography and Interventions. Such critical gaps in patient-provider communication create a significant barrier to device usage, as the condition remains unidentified and untreated within a large demographic. Consequently, the market experiences suppressed growth rates, with the actual clinical demand falling considerably short of its prevalence-based potential.

Market Trends

A prominent structural transformation in the peripheral vascular market involves the migration of procedures to Ambulatory Surgical Centers (ASCs) and Office-Based Labs (OBLs), a trend driven by favorable reimbursement models and enhanced operational efficiency. This shift enables reduced overhead costs while maintaining clinical safety for interventions like angioplasty, necessitating that manufacturers adapt their commercial strategies to cater to independent facilities rather than solely large hospital networks. According to an American College of Cardiology analysis in November 2025, which examined fee-for-service claims in 'Studies Examine Current Treatments and Trends For Peripheral Vascular Interventions,' the proportion of total revascularizations performed in ASC and OBL environments has surged to 47% of the total procedural volume. Simultaneously, the widespread adoption of Intravascular Lithotripsy (IVL) is redefining the treatment of heavily calcified lesions that often complicate endovascular outcomes. Unlike traditional balloons, IVL utilizes sonic pressure waves to fracture calcium deposits within the vessel wall, thereby optimizing vessel compliance prior to stent deployment and enabling successful revascularization in complex cases. This technology has become essential for treating advanced peripheral artery disease, directly fueling revenue expansion for major industry players. For instance, Johnson & Johnson's Cardiovascular segment delivered a reported sales increase of 12.6% in its 'Q3 2025 Results' (October 2025), a growth trajectory primarily attributed to the accelerating global demand for its Shockwave intravascular lithotripsy platform.

Key Market Players

• Abbott Laboratories
• AngioScore Inc.
• Edward Lifesciences Corporation
• Medtronic Plc.
• Teleflex Inc.
• Volcano Corporation
• Boston Scientific Corporation
• Cook Group Inc.

Report Scope

In this report, the Global Peripheral Vascular Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peripheral Vascular Devices Market, By Type

• Peripheral Stents
• PTA Balloons
• Catheters
• Endovascular Aneurysm Repair Stent Grafts
• Plaque Modification Devices
• Peripheral Accessories
• Inferior Vena Cava Filters
• Hemodynamic Flow Alteration Devices

Peripheral Vascular Devices Market, By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers

Peripheral Vascular Devices Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peripheral Vascular Devices Market.

Available Customizations:

Global Peripheral Vascular Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).